Researchers from the US have shown that combination therapy with sitagliptin and metformin results in a substantial and additive glycemic improvement in patients with type 2 diabetes. Sitagliptin ...

As a new class of OADs, DPP-4 inhibitors have many important advantages over other currently available antidiabetic drugs. Compared with currently available insulin secretagogues, DPP-4 inhibitors ...

In the USA, patients with T2DM are treated with sitagliptin as monotherapy as an adjunct to diet and exercise, or in combination with metformin or TZD. Recently, the US FDA approved Janumet as ...